Edition:
United Kingdom

Camurus AB (CAMX.ST)

CAMX.ST on Stockholm Stock Exchange

105.00SEK
10:23am BST
Change (% chg)

1.00kr (+0.96%)
Prev Close
104.00kr
Open
104.20kr
Day's High
105.20kr
Day's Low
104.20kr
Volume
4,220
Avg. Vol
25,767
52-wk High
147.80kr
52-wk Low
91.30kr

Latest Key Developments (Source: Significant Developments)

Camurus Q1 Operating Loss SEK 46.4 Mln
Thursday, 3 May 2018 

May 3 (Reuters) - CAMURUS AB ::Q1 NET SALES MSEK 14.6 (17.2)..Q1 OPERATING RESULT MSEK -46.4 (-51.6).BOARD OF DIRECTORS HAS NOT CHANGED ITS OUTLOOK ON FUTURE DEVELOPMENTS.  Full Article

Camurus Q3 operating loss widens to SEK ‍67.1​ million
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - CAMURUS AB :Q3 NET REVENUE SEK ‍12.5​ MILLION VERSUS SEK 30.5 MILLION YEAR AGO.Q3 OPERATING LOSS SEK ‍-67.1​ MILLION VERSUS LOSS SEK 16.6 MILLION YEAR AGO.  Full Article

Camurus Q2 loss after tax narrows to SEK 20.6 million
Thursday, 14 Jul 2016 

Camurus AB : Q2 revenue 25.8 million Swedish crowns ($3 million) versus 22.7 million crowns year ago .Q2 loss after tax 20.6 million crowns versus loss 115.2 million crowns year ago.  Full Article

Camurus: Safety and local tolerability of CAM2029 in Phase 2 study was good
Tuesday, 12 Jul 2016 

Camurus AB : Announces completion of Phase 2 study of CAM2029 in patients with acromegaly and neuroendocrine tumors . In present study treatment with CAM2029 resulted in therapeutic blood-levels of octreotide over four weeks . Safety and local tolerability of CAM2029 was good and consistent with marketed reference product Sandostatin Lar .As next step looks forward to initiation of planned Phase 3 trials by collaborator Novartis.  Full Article

BRIEF-Camurus Q1 Operating Loss SEK 46.4 Mln

* BOARD OF DIRECTORS HAS NOT CHANGED ITS OUTLOOK ON FUTURE DEVELOPMENTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)